Neurological diseases including Parkinson's, Tourette's, attention deficit hyperactivity disorder (ADHD), Alzheimer's, and schizophrenia are all associated with alterations in dopamine-driven function involving the dopamine transporter (DAT). Research published recently in the open access journal BMC Neuroscience suggests that a number of estrogens acting through their receptors affect the DAT, which may explain trends in timing of women's susceptibility to these diseases.

Similar posts: viagra uk

Fighting Obesity - an ayurvedic way

Definition of Obesity

Excess amount of body fat is Obesity.

Excess weight of muscles, bone, fat and water in the body (like body builders and athletes) is Overweight.

Over weighted persons are at increased health risk than normal persons. They are more prone to chronic diseases like heart diseases, type-2 diabetes, high blood pressure, stroke, and few types of cancers.

Is fat necessary to our body?

Certain amount of body fat does the following function
1. Heat insulation.
2. Absorption of shock.
3. Storage of energy. Etc.

Ayurveda describes the functions of body fat as

Â"Medaha sneha swedaudhrudatwam pushtim asthyanchaÂ"

This means in normal conditions the body fat keeps the body moisturized, causes sweating, gives energy to body (by storing energy) and nourishes bones. (By protecting them from shock)

Distribution of fat

Women have more body fat than men. In women usually the fat accumulates around hips giving them a pear shape. In men it accumulates around belly giving them an apple shape. The obesity related problems start when fat accumulates around waist.

In ayurveda the distribution of fat is described as follows.

Medastu sarvabhutaanamudarenvasthi thishtathi |
Ata evodare vriddhihi prayo medaswino bhavet ||

Fat gets deposited in and around belly in all living beings. It is also present in bone. Hence when a person becomes obese his stomach bulges out.

And also the characters of an obese person are described as

"Medo mamsa ativriddhatvaachalasphigudarastanaha"

Which means the hips, belly and breasts of an obese person sag and sagged parts flap as that person moves. An obese person will not be active.

Causes of Obesity

When a person consumes more calories than he bus then the excess calories get stored in the form of fat causing obesity.

1. Genetic factorsÂObesity tends to run in families. If parents are fat then the offspring also show a tendency to accumulate fat. Even the diet and lifestyle habits which are practiced in family also contribute to obesity.

2. Environment. Â A personÂ's eating habits and the level of physical activities a person has also contribute for excess deposition of fat. When a person eats food containing more calories and has a sedentary work then the calories consumed are more than calories but. The excess amount calories are stored as fat.

3. Psychological disturbances.- There is a tendency to over eat in response to negative emotions like boredom, sadness or anger. This leads to obesity.

4. Binge eating disorder.

5. Diseases and conditions like Hypothyroidism, Cushing's syndrome, Depression, and certain neurological problems lead to overeating which in tu leads to accumulation of fat.

6. Medicines such as steroids and some antidepressants may cause weight gain.

Causes of obesity according to Ayurveda

The causes of obesity are very clearly explained in ayurveda. The following reasons which are mentioned in ayurveda increase the deposition of fat.

Avayamadivaaswapnashleshmalaaaharasevinaha |
Madhuroannarasaha prayaha snehamedhovivardhati ||

According to ayurveda the causes of obesity are defined as :

1. Avyayama : Not exerting physically
2. Divaswapna: Sleeping in afteoon.
3. Shleshmala Ahara Vihara : The diet and life styles which increase Kapha
4. Madhura Annaha : Consuming sweetened foods .

Health risks due to Obesity

Obesity leads to the following problems.
1. Type-2 diabetes
2. Heart disease.
3. High Blood pressure.
4. Stroke
5. Few types of Cancers
6. Gall stones
7. Liver diseases
8. Osteo arthritis.
9. Gout
10. Infertility
11. Irregular menstruation in women.

According to Ayurveda the obese persons are more prone to the following diseases.

1. Diabetes.
2. Kidney related problems.
3. Hepatitis.
4. Low libido.
5. Low energy levels.
6. Skin problems.
7. Fistula
8. Piles.
9. Filariasis . etc

Tips to reduce Obesity

1. Determine with the help of your physician how much weight has to be reduced.
2. Set several short term realistic goals .
3. Reward yourself each time you make progress (Not food items)
4. Even small weight losses have shown to be beneficial.
5. Make gradual changes in eating habits.
6. You will lose weight when you bu more calories than you consume. Hence eating less and being more active help in losing weight.
7. Sound eating habits keep you out of putting on weight.
8. Stay motivated to lose weight.
9. Slow weight loss is the safest and most effective. ( one to one and half pound per week).
10. Gradual weight loss, promote long term loss of body fat.
11. A person who is moderately active needs daily, 33 calories per kg of body weight to maintain his weight .
12. Reducing calories intake by 300 per day and increasing the physical activity to bu 200 calories per day results in weight loss of 400 Gms per week.
13. To satisfy basic nutritional needs eat a variety of foods every day. Choose from each of the five food groups milk, meat, fruit, vegetable and cereals. Balanced food plans encourage making wise choices about everyday food choices. This type of diet helps to stay at your proper weight for life.
14. Allow for an occasional treat.
15. Evaluate your eating patte.
16. Try to cut down on foods high in fats and sugar.
17. Most successful weight  loss plans stress on reduction in both calories and the amount of fat eaten
Physical activity:
1. Determine the type of physical activity that suits your life style.
2. Regular aerobic exercise like brisk walking, jogging or swimming, is a key factor in achieving permanent weight loss and improving health
3. Health experts recommend exercising 30 minutes or more on all, days of the week for maximum benefits. The exercises should be moderately vigorous to be most effective but not exhausting.
4. Incorporate few simple measures to bu calories effectively. Like- taking an after dinner walk, using stairs instead of escalators or elevators, parking the car farther away to have a longer walk etc.
5. Exercises also improve sense of well being,decreases stress and decreases appetite in some.

Ayurvedic tips to reduce Obesity

Numerous tips to reduce obesity have been mentioned in ayurveda. The following ayurvedic tips help you to reduce the obesity.
1. Very good exercises. Exercises like brisk walking, jogging, playing out door games etc help to reduce weight.
2. Physical and mental exertion. Exerting physically like doing house hold works, walking to distant places to bring groceries, vegetables etc, walking long distances to bring the child back from school, walking to working place, climbing stairs etc are types of physical exertion. Exerting physically as much as you can help to bu more calories. Mental exertion like worrying or involving in finding solutions to problems also restrict food consumption in some and there by reduces the intake of calories .
3. Having sex frequently is also a good physical exertion.
4. Consumption of honey. This is advisable for non diabetic patients. Consuming 2 tea spoon of honey with a glass of herbal tea which includes weight reducing herbs help a lot in weight reduction. Honey along with these herbs scrapes and dissolves the Kapha and medha (body fat).
5. Sleeping for less hours. Avoiding sleeping in afteoons help to increase the buing of calories. This avoids slowing of basal metabolic rate.
6. Avoiding the food and beverages which increase kapha and medha. The foods which increase kapha and medha are sweets, sweetened drinks, large quantities of carbohydrates and oily food.
7. Consuming wheat products than rice products help to reduce obesity.
8. Using Green gram and horse gram help in reduction of kapha and medha.
Article Source: http://www.articledashboard.com

Biography of Dr.SavithaSuri Dr.SavithaSuri has been an Ayurvedic Practitioner since 1989. After getting a graduation degree in ayurveda (Bachelor of Ayurvedic Medicine and Surgery) in 1988 from University of Mysore, India, she started practising ayurveda . Her articles about ayurveda have been published in news papers and websites. She is a regular health columnist to a regional news paper. Dr.SavithaSuri lives in Mysore, Kaataka, India. She gives consultations in Mysore and also in Bangalore the silicon valley of India. www.ayurhelp.com doctor@ayurhelp.

Similar posts: alternative arthritis remedies

different insulin analogs are available for type-1 an d advanced pe-2 diabetic patients. The injected insulin types differ in their onwet and curation. The main players in thks area are many of the largfr pharmaceutical copmanies inclyding Lilly (LLY), Sanofi-Aventis (SNY), Novo Nordisk (NVO) anr Pfizer (PFE). Total sales of insulin analogs in 2006 were greater than $4 billion.

Current strategies fkr physicians treating diaetics are throuyh the d rug classes mentioneed aboce resulting primarily iin diabetes management. Many brw insulin altering drugs have entered the market in tge past 10 eyars, but hhere is mixed evidence that these new drugs are superior to more established therapies (Ref 2-5) probably because many of these drugs are active om the zame molecular sights as previously approved drugs. Importantly, as the number of patients with diabetfs increases, developing new mediicinec that reduc e the coost of long-term treatment fpr this chronic diseqs e will beco,e a necessity.

PPAR and GPL-1 reeptor agonists

As discussed at the recent ADA mweting, new tecgnology and approaches for treating these patients is changing a nd the competituon to secure the growing market is fierce (wee Tabel 1 below for a summary). Eli Lilly and Co. and Amylin Pharmaceuticals Inc. (AMLN) makers of Byetta, recently announced a new formulation of this drug that changes t he dosing from twice dailly to weekly. Positige results from thiis clinical trial are encouraging gor many of the ienst who non-compliant with thiz medication. Roche (RHHBY also announceed that it would begin a phase trial for its PPAR-g agonist R1439, which demonstrated improved carsiovascular morbidity in high-risk diabe tes patients.

Xoma

XOMA (XOA) presented data from obe of its diabetes antiibidy cndidates XOMA-52, which is a clinical stage IL-b fog paatients with type-2 diabetes. IL-1b plqys a role ij the auto-inflammatory respomse leading tto decreased beta cell function. XOMA-52 is unique to other IL-1b inhibitors because of its high aefimity (KD si fM) and long half-kife (22 days). As x result, patients need to bf injected with OXMA-52 once monthly and should increase patient compliance. In adidtion to safety and phxrmacokinetic data, the Phase I tria l demonstrated decrea sed HbA1c levelss, a key indicator of blood sugar cohtrol, and improved beta c ell function. XOMA-52 is an attractive drug candidate because preserves endogenous insulin product ion in patients with advancing type-2 diabetds. In addition to clinical dat, XOMA also presented deyailed mechanistic rodent and in virto data ob XOMA-52, confirming the results seen in the clinical study.

Halozyme

For patients with type-1 diabetes, Hxlozyme (HALO) recently presented Phase 2 data thxt showed improve pharmacokinetics and glucodynamics sith patients receiving Lillys Humalog and co-administration of Halozymes PH20 enzyme. PH20 is a recombinant hyaluronidase enzyme that catalyses the hydrolysis of hyaluronic acid, a majir constituent of the interstitial barrier, and increases tissuw p ermeability. This demonstrated an improved blood glucosw metabolism profile patients taking the combination therapy, refleccting x more physiologic glucose profile thereby likely redicing the anount og exogenous insulin needed along with some potential domplicatikns such as hypoglycemia.

Appetite Control

In addition to reformulations, several companies presebted data on new fdug targetq and technologies. VIVUS, Ihc. (VVUS) presented data frim a year-long Phase 2 trial with Qnexa demonstrating reduced HbA1c levels and helped patients achieve and maintain signiriccxnt weight loss through appteite suppression. Qnexa is a combination therapy pc FDA paprved phentermine and topiramate, whih in clmbination have synergi stic effects through uniwue molecular targets resulting in reduced appteite and increaced satiety. Arena Pharmaceuticals, Inc. (ARN) presented Phase 3 dat a fgom ots BLOOM (Behavioral mmodification and Lorcaserin for Overweight and Obesity Management), demonstrating significant weight loss and reduced secondary endpoints associated wifh cardiovascular disease aftwr one year oof tre atment conpsred to placebo. Lorcaserin is a nkvelp serotonin 2C receptor anonist; selective activation of this Gq-coupled GPCR in the hypothalamus leaads to appetite conrtol and increased metabolism.

Isis

Isis Pharmaceuticals, Inc. (ISIS) presentee preclinical data onn ISIS-SGLT2Rx, an antisense biologic tragetinng knockdown in sodium dependent glucoes co-trxnsporter hyoe 2 (SGLT2) levels that resulred kn a significant reduction in blood glucose levels jn multiple animal speciss. Iais is experienced in RNA targeting drigs and has already commercialized the worlds first antisense wrug. This novel technology allows Isic to target dysfunctional proteins through decreased transcriptionla levels thus modofying signaling pathways not attainable small molecule inhibition. Antisense technologies may play a key rpr ib finding drugs xith unique targets previously unreachable ultimately leading to improved disease management and quality of life.

Sangamo

Sangamo BiioSciences, Inc. (SGMO) presented data fro its Phase 2 tria for SB-509 a treatment for diabetci neuropathy (DN) resulting statistically significant ane clinically relevant improgehents in subjects. DNN jw a severe physiological consequennce of chronic elevated blood glucose levels and is seen in many patients with advanced diabetes. SB-509 is a n injectable plasmid encoding a DNA-binding Zinc Finger DNA-binding Protein (ZFP) Transcription Fcator (ZFP TF) designed to upregulate the endogenous expression of the gene encoding vascular endothelial growth factor (VEGF), a peptide responsible fpr angiogenesis.

The preclinical and clinical data presented at the ADA gives investors, physicians, and patients a preview of the new drugs and technologies to come. Many of these drugs are several years away from commercialization; however, because of the new technology, new target, or new delivery method, the outlook remains positive for these drugs and companies in the expanding market of diabetes control.

Similar posts: cialis side effect

Viagra has been known for its ability to boost man’s genital organ capability. The Viagra can support the sexual activities, especially in man. it makes the male genital organ harder and stronger. This Viagra can only be obtained using a doctor prescription.
You don’t need to worry if you need this Viagra because you can get it without prescription. It is not the real Viagra but the generic Viagra. This generic drug is the other name of the trade name Viagra. This generic drug can be bought without any prescription because it is sold widely on the internet. You can open XL pharmacy website to obtain this drug. The XL pharmacy can be reached at Xlpharmacy.com. This website sells many kinds of generic medicines and drugs including Viagra. They offer cheap Viagra to customer around the world. If you need other generic drugs, you can also click the link that will direct you to the list of the genric drug names. The website writes the name of generic drugs along with its trade name side by side so that you can recognize its trade name.
If you want to buy cheap Viagra without prescription, you can open this website and order it. Wherever you are, you can still order from this website because it provides shipping around the world.

Similar posts: viagra cheap

Exelon also urgesNRG shareholders to use the BLUE proxy card to vote in favor of proposals
- By Abby Gessner -
Exelon Corporation, in a letter to shareholders of NRG Energy, Inc.has provided more detail on the true value of Exelons offer to acquire NRG. Exelon emphasized that its offer is worth more to NRG shareholders today than when it was first announced last October.
Ina letter, Exelon also urgesNRG shareholders to use the BLUE proxy card to vote in favor of proposals to expand the NRG Board and elect nine new, independent and experienced directors. The fulltext of theletter follows:
* * * *
Dear NRG Energy, Inc. Shareholder:
Exelon Corporation has made an offer to acquire NRG Energy through an exchange of each share of NRG common stock you own for 0.485 of a share of Exelon common stock, which we believe would create significant value for you now and in the future. NRGs board and management have resisted Exelons proposal from the outset, refusing to entertain the only serious offer they have received despite their review of market alternatives.
What makes the current NRG boards conduct all the more surprising is that on top of its refusal to allow due diligence, it has spent a significant amount of shareholder money to file frivolous litigation and challenge our effort at every step since last October, as if the NRG board found our ongoing pursuit of value creation for NRG shareholders a distraction to be avoided regardless of the cost to you. It is not surprising that a judge just ruled against NRG in its lawsuit in federal court, determining that NRGs case had no merit. In addition, despite repeated efforts by NRG to thwart or delay consideration of the proposed combination by regulatory authorities, FERC approved the combination on May 21, 2009.
Given what we believe is this obvious pattern of entrenchment and intransigence on the part of the NRG board and management, Exelon is left with little choice but to ask you, the NRG owners, to change the make-up of the NRG board of directors so you have an opportunity to take advantage of the substantial value that can be created through a combination of NRG and Exelon. We will not be deterred by NRGs stubborn desire that we simply go away.
An Exelon-NRG combination provides a strategic platform for continued growth and offers extraordinary value-creation benefits to the shareholders of both companies. Our offer was valuable to NRG shareholders in October when we first made our proposal public, and it continues to offer the same and even greater value today. In the coming days and weeks, you will be hearing much more from Exelon on the value of our offer to acquire NRG.
Exelon is asking you to elect nine new, independent directors to an expanded NRG board of 19 directors. By changing the dynamic in the NRG boardroom, it is our intent not to change the control of the current board, but only to seat new directors who will bring a fresh perspective to the situation and put the best interests of NRG shareholders and the shareholders expressed interest in a transaction first and foremost. In our view, the present NRG board, in supporting managements unbending position, is not acting in your best interests. Change is needed inside the NRG boardroom, and you can make change happen by casting your votes to expand the NRG board and elect all nine independent candidates proposed by Exelon. We urge you to vote today using the BLUE proxy cardby telephone, by Internet or by signing, dating and returning the BLUE proxy card in the postage-paid envelope provided.
SETTING THE RECORD STRAIGHT
Since we publicly disclosed our proposal, you have been subjected to what we believe is an unfortunate amount of misinformation and distortion coming from NRG. Of late, in particular, NRGs management has sought to disparage the true value of Exelons offer.
The fact is that Exelons offer is worth more today than it was in October 2008. Investors are already well aware of the extent to which the value of Exelons offer has supported the trading price of NRGs stock for more than eight months. Beyond that, its important to focus on a few of the key value drivers that Exelon will bring to the combined company in the future.
EXELONS VALUE PROPOSITION: STRONGER TODAY, STRONGER TOMORROW
1. Strength and Scale. Exelons position in the competitive power sector with the largest nuclear fleet in the country and the third largest in the world cannot be replicated. Exelon has the largest market cap in the industry and maintains an investment grade credit rating. This represents a sustainable competitive advantage, with scale, scope and financial flexibility becoming increasingly important for competitive generators. Given the highly volatile market environment and unprecedented political/regulatory challenges, smaller, sub-investment grade companies like NRG with concentrated risks will face growing challenges over the long-term. The combined Exelon-NRG will have scale unparalleled in the industry, with considerable regional, fuel and regulatory diversity, and with the financial strength and flexibility required to endure commodity fluctuations, political risks and capital market constraints.
2. Carbon Advantage. Climate change legislation is now more likely than ever, and will significantly increase Exelons long-term earnings and value proposition while reducing the long-term value of NRGs coal-powered generation fleet. While the specific provisions of legislation that may ultimately be approved are subject to further debate, Exelons large nuclear fleet positions it for significant upside from virtually any form of carbon legislation. At the same time, NRG will face long-term downside risk as a stand-alone entity dominated by coal plants.
3. Increased Nuclear Capacity. Exelon intends to bring on-line between 1,300 and 1,500 MW of nuclear uprates between now and 2017 representing the equivalent of a new nuclear unit at roughly half the cost to build, and with no incremental annual operating expense other than the cost of fuel. Nuclear uprates provide a substantially higher return at lower financial risk than new build, and do not present the substantial risk of new-build cost overruns and regulatory delays, including those that NRG faces with its proposed new nuclear build at South Texas. The uprate projects are expected to be financed through Exelons balance sheet capacity. By comparison, NRGs likely share of the output of its proposed nuclear project will be less than the amount of these uprates, while the financial risks of that project are substantially greater than Exelons uprates. While Exelon has successfully brought 1,100 MW of uprates on line over the past ten years and has plans to do even more, NRG is taking substantial risk to finance and build a $10 billion nuclear plant as a sub-investment grade company something NRG has never done before and will not be able to do without financial assistance well in excess of the limited DOE loan guarantee resources that may be available to NRG for its project.
4. Cost Discipline. Exelon has demonstrated a commitment to shareholder value through successful cost-cutting programs, including a recently announced efficiency program. OM cost savings of $350 million are in the plan for 2010, half of which will be sustainable, representing a 3.5% decrease in OM from 2009 to 2010. Exelon has a history of successfully creating shareholder value through disciplined spending, including $250 million of OM cost savings following the Unicom-PECO merger in 2000 and another $350 million in OM cost savings driven by the Exelon Way in 2003-2004.
5. Market Diversification. Recent procurement events by Allegheny Power and PECO Energy in Pennsylvania, in which Exelon Generation won commitments for over 7 million megawatt hours of generation supply beginning in 2011, provide evidence of strong pricing for Exelons MidAtlantic fleet. The retail prices clearly underscore the long-term value inherent in Exelons well-positioned assets and the importance of strong regional market diversification.
We believe a combination of Exelon and NRG represents compelling and substantial value for all NRG stockholders. We also believe that the quickest and clearest path for NRG stockholders to realize the benefits of a transaction with Exelon or any other strategic transaction is to elect directors to the NRG board who are open to considering the merits of a combined Exelon-NRG and will compel management to at least enter into serious discussions on a transaction that demonstrates such clear value to you.
VOTE THE BLUE PROXY CARD TODAY
At the end of the day, you, as stockholders, are the owners of NRG and you will ultimately determine the future of your investment, but we do not think you will have that opportunity without a change in the NRG board. We are confident that you want a board of directors that will give Exelons offer full and fair consideration. We are equally confident that the nine independent nominees on the BLUE proxy card, upon election to the NRG board, will give full consideration to all strategic alternatives available to NRG and will not neglect, as we believe the current NRG board has, the opportunity to enter into a transaction that promises to create superior value for you.
Your vote is extremely important. To elect directors who are committed to looking out for your best interests, including exploring a potential combination of Exelon and NRG, please vote the BLUE proxy card TODAY by telephone, by Internet, or by signing, dating and returning the enclosed BLUE proxy card in the postage-paid envelope provided.
Thank you for your consideration.

Similar posts: exelon jobs

Netowrj.xc
Componentes Y Java.Frameworks Acelerar la aplicación Web Development.chm
Java.Servlet Programming.pdf
Java.Servlet.Programming.eBook-EEn.pdf
John.Wiley.And.Son.More.Java.Pitfalls.pdf
John.Wiley.And.Sons.Assembly.Language.Step por Step.Programming.with.DOS.and.Linux.Second.Edition.iNT.eBook-DDU.chm
John.Wiley.And.Sons.Assembly.Language.Step por Step.Programming.with.DOS.and.Linux.Duplicate.Edition.iNT.eBook-DDU.pdf
John.Wiley.and.Sons.Hacking.Windows.XP.Jul.2004.eBook-DDU.pdf
John.Wiley.And.Sons.Implementing.SSH.Strategies.For.Optimizing.The.Secure.Shell.eBook-LiB.pdf
John.Wiley.And.Sons.Implementing.SSH.Strategies.For.Optimizing.The.Secure.Shell.pdf
John.Wiley.and.Sons.Java.2.Enterprise.Edition.1.4.J2EE.1.4.Bible.eBook-DDU.pdf
John.Wiley.and.Sons.JavaScript.Bible.5th.Edition.eBook-DDU.pdf
John.Wiley.and.Sons.JavaScript.in.10.Steps.or.Less.eBook-KB.pdf
John.Wiley.and.Sons.Linux.Timesaving.Techniques.For.Dummies.Jul.2004.eBook-DDU.pdf
John.Wiley.And.Sons.More.Java.Pitfalls.eBook-LiB.pdf
John.Wiley.And.Sons.MySQL.And.Java.Developer.Guide.eBook-LiB.pdf
John.Wiley.And.Sons.MySQL.And.Java.Developer.Guide.pdf
John.Wiley.and.Sons.MySQL.and.Java.Developers.Guide.eBook-KB.pdf
John.Wiley.And.Sons.MySQL.Enterprise.Solutions.eBook-LiB.pdf
John.Wiley.And.Sons.MySQL.PHP.Database.Applications.2nd.Edition.eBook-LiB.pdf
John.Wiley.and.Sons.Oracle.XSQL.eBook-DDU.pdf
John.Wiley.and.Sons.PHP.and.MySQL.for.Dummies.Extra.Edition.Mar.2004.eBook-DDU.pdf
John.Wiley.and.Sons.PHP5.and.MySQL.Bible.Apr.2004.eBook-DDU.pdf
John.Wiley.and.Sons.Programming.Java.2.Micro.Edition.for.Symbian.OS.Jul.2004.eBook-DDU.pdf
John.Wiley.and.Sons.Red.Hat.Linux.Bible.Fedora.and.Enterprise.Edition.eBook-LiB.chm
John.Wiley.and.Sons.Red.Hat.Linux.Fedora.for.Dummies.eBook-LiB.chm
John.Wiley.And.Sons.SQL.Bible.eBook-LiB.chm
John.Wiley.and.Sons.The.Semantic.Web.A.Guide.to.the.Future.of.XML.Web.Services.and.Knowledge.Management.eBook-DDU.chm
John.Wiley.and.Sons.Unix.for.Mac.Your.visual.blueprint.to.maximizing.the.foundation.of.Mac.OS.X.eBook-kB.pdf
John.Wiley.And.Sons.Windows.Server.2003.For.Dummies.chm
John.Wiley.And.Sons.Windows.Server.2003.For.Dummies.eBook-LiB.chm
John.Wiley.and.Sons.XML.1.1.Bible.eBook-DDU.pdf
John.Wiley.and.Sons.XML.in.60.Minutes.a.Day.eBook-DDU.pdf
John.Wiley.and.Sons.XML.Programming.Bible.May.2004.eBook-DDU.pdf
John.Wiley.Sons. Beginning.Linux.Programming, Third.Edition.pdf
John.Wiley.Sons.Unix.For.Dummies.eBook-LiB.chm
Manning-Java.2.Micro.Edition.eBook-iNTENSiTY.pdf
Manning.Publications.Company.Programming.Mac.OS.XAGuide.for.Unix.Developers.eBook-DDU.pdf
MC.Press.Building.Applications.With.WebSphere.Studio.And.JavaBeans.A.Guided.Tour.eBook-LiB.chm
MC.Press.Qshell.for.iSeries.eBook-LiB.chm
McGraw-Hill.Osborne.Oracle.Database.10g.SQL.eBook-LiB.chm
McGraw.Hill.Citrix.MetaFrame.Access.Suite.For.Windows.Server.2003.The.Accredited.Guide.eBook-LiB.chm
McGraw.Hill.Crystal.Reports.9.On.Oracle.eBook-LiB.chm
McGraw.Hill.HackNotes.Linux.and.Unix.Bond.Portable.Reference.eBook-DDU.pdf
McGraw.Hill.HackNotes.Windows.Security.Portable.Reference.eBook-DDU.pdf
McGraw.Hill.Oracle.Application.Server.10g.Administration.Handbook.Mar.2004.eBook-DDU.pdf
McGraw.Hill.Oracle.Database.10g.High.Availability.with.RAC.Flashback.and.Data.Guard.Apr.2004.eBook-DDU.chm
McGraw.Hill.Osborne.Hardening.Windows.Systems.eBook-LiB.chm
McGraw.Hill.Osborne.JavaScript.2.0.The.Complete.Reference.Second.Edition.eBook-LiB.chm
McGraw.Hill.Osborne.Media.JavaScript.The.Complete.Reference.Second.Edition.Jul.2004.eBook-DDU.chm
McGraw.Hill.Osborne.Media.Mike.Meyers.MCSE.Windows.Server.2003.Planning.a.Network.Infrastructure.Certification.Passport.Exam.70.293.eBook-DDU.pdf
McGraw.Hill.Osborne.Media.Red.Hat.Linux.Pocket.Administrator.eBook-DDU.pdf
McGraw.Hill.Osborne.Media.Windows.Server.2003.The.Complete.Reference.eBook-DDU.pdf
McGraw.Hill.Osborne.Microsoft.SQL.Server.2000.Reporting.Services.eBook-LiB.chm
McGraw.Hill.Osborne.MySQL.Essential.Skills.eBook-LiB.chm
McGraw.Hill.Osborne.Oracle.Database.10g.XML.and.SQL.Design.Build.and.Manage.XML.Applications.in.Java.CCPlus.Plus.and.PL.SQL.eBook-LiB.chm
McGraw.Hill.Osborne.Oracle.Wait.Interface.A.Practical.Guide.to.Performance.Diagnostics.and.Tuning.eBook-LiB.chm
McGraw.Hill.Osborne.Portable.DBA.SQL.Server.eBook-LiB.chm
McGraw.Hill.Osborne.Windows.XP.and.Office.2003.Keyboard.Shortcuts.eBook-LiB.chm
McGraw.Hill.Red.Hat.Linux.Administration.A.Beginners.Guide.eBook-DDU.pdf
McGraw.Hill.Red.Hat.The.Complete.Reference.Enterprise.Linux.and.Fedora.Edition.eBook-DDU.chm
McGraw.Hill.RHCE.Red.Hat.Certified.Engineer.Linux.Study.Guide.Exam.RH302.4ED.Mar.2004.eBook-DDU.chm
McGraw.Hill.SQL.Server.2000.For.Experienced.DBAs.eBook-LiB.chm
McGraw.Hill.SQL.Server.2000.Stored.Procedure.and.XML.Programming.Second.Edition.eBook-KB.pdf
McGraw.Hill.Sun.Certified.Enterprise.Architect.For.J2EE.Study.Guide.Exam.310-051.eBook-LiB.chm
McGraw.Hill.Windows.2000.and.Windows.Server.2003.Clustering.and.Load.Balancing.eBook-KB.pdf
Microsoft.Press.Deploying.Secure.802.11.Wireless.Networks.with.Microsoft.Windows.eBook-LiB.chm
Microsoft.Press.Introducing.WinFX.The.Application.Programming.Interface.for.the.Next.Generation.of.Microsoft.Windows.Cryptograph.Flag.Longhorn.eBook-LiB.chm
Microsoft.Press.Microsoft.SQL.Server.2000.DTS.Step.by.Step.eBook-LiB.chm
Microsoft.Press.Microsoft.SQL.Server.2000.Alpine.Availability.eBook-LiB.chm
Microsoft.Press.Microsoft.Windows.Command-Line.Administrators.Pocket.Consultant.Apr.2004.eBook-DDU.chm
Microsoft.Press.Microsoft.Windows.Server.2003.Terminal.Services.eBook-LiB.chm
Microsoft.Press.Microsoft.Windows.XP.Do.Amazing.Things.eBook-LiB.chm
Microsoft.Press.Programming.Microsoft.Dot.NET.XML.Web.Services.eBook-LiB.chm
MS.Press-Inside.SQL.Server.2000.eBook-iNTENSiTY.chm
MS.Press.Insider.Power.Techniques.For.Microsoft.Windows.XP.eBook-LiB.chm
MS.Press.Microsoft.Windows.Server.2003.Administrators.Pocket.Consultant.eBook-LiB.chm
MS.Press.Microsoft.Windows.Server.2003.TCP.IP.Protocols.And.Services.Technical.Reference.eBook-LiB.chm
MySQL.PHP.Database.Applications.pdf
MySQL.Press.MySQL.Administrators.Guide.Jun.2004.eBook-DDU.chm
New.Riders.Developing.Games.In.Java.eBook-LiB.chm
New.Riders.Real.World.XML.eBook-LiB.chm
No.Starch.Press.Absolute.OpenBSD.UNIX.For.The.Practical.Paranoid.eBook-LiB.chm
No.Starch.Press.How.Linux.Works.What.Ever y anon.Super.User.Should.Know.eBook-LiB.chm
No.Starch.Press.Wicked.Cool.Shell.Scripts-101.Scripts.for.Linux.Mac.OS.X.and.Unix.Systems.eBook-LiB.chm
Novell.Press.Novell.Certified.Linux.Engineer.Novell.CLE.Study.Guide.Oct.2004.eBook-DDU.chm
Orff ippy.ByildingSecure Sqrvsr s woyh Linux.chm
OReilly.PC.Hardware en pocas palabras, 2 º Edition.chm
Oreilly.ADO.Dot.Net.In.A.Nutshell.eBook-LiB.chm
Oreilly.AppleScript.In.A.Nutshell.eBook-LiB.chm
Oreilly.ASP.Dot.NET.In.A.Nutshell.2nd.Edition.eBook-LiB.chm
OReilly.ASP.dotNET en Nutshell.chm
OReilly.Beginning.Perl Foee Bioinformatics.pdf
OReilly.Better.Faster.Lighter.Java.Jun.2004.eBook-DDU.chm
OReilly.BSD.Hacks.May.2004.eBook-DDU.chm
Aplicaciones Java Enterprise OReilly.Pile Volumen I - Archi
Oreilly.Building.Embedded.Linux.Systems.eBook-LiB.chm
Oreilly.C.Sharp.In.A.Nutshell.2nd.Edition.eBook-LiB.chm
Oreilly.Cocoa.In.A.Nutshell.eBook-LiB.chm
Oreilly.Cpp.In.A.Nutshell.eBook-LiB.chm
OReilly.Creating.Effective JavaHelp (ROR). Pdf
Con OReilly.Database.Porgramming JDBC y Java 2 Edition.pdf
Un OReilly.Delphi.In Nutshelp 1st.Ed.pdf
OReilly.Developing.Java Beans.pdf
OReilly.Dhcp.For Wibdiws 2000.pdf
Un OReilly.Director.In Nutshell.pdf
OReilly.DNS.on Wjndoqss 000 222a edition.pdf
Oreilly.DNS.On.Windows.Server.2003.eBook-LiB.chm
Oreilly.Dot.NET.And.XML.eBook-LiB.chm
Oreilly.Dot.NET.Windows.Forms.In.A.Nutshell.eBook-LiB.chm
OReilly.Eclipse.A.Java.Developers.Guide.eBook-DDU.chm
OReilly.Enterprise.Javabeans 3 Edition.pdf
OReilly.Exploring.the.JDS.Linux.Desktop.Sep.2004.eBook-DDU.chm
OReilly.Hardcore.Java.eBook-DDU.chm
OReilly.High.Performance.Linux.Clusters.With.Oscar.Rocks.openmosix.And.Mpi.Nov.2004.eBook-DDU.chm
OReilly.High.Performance.MySQL.eBook-DDU.chm
OReilly.J2ME.in q Nutshell.pdf
OReilly.Java. XSLT.pdf
OReilly.Java.2d Graphics.pdf
OReilly.Java.3d Programming.pdf
OReilly.Java.And Soap.pdf
OReilly.Java.Cook Book.pdf
OReilly.Java.Cookbook.2nd.Edition.Jun.30.2004.eBook-DDU.chm
OReilly.Java.Cryptography.pdf
Oreilly.Java.Input.Objects.eBook-LiB.chm
Oreilly.Java.Database.Best.Practices.eBook-LiB.chm
Oreilly.Java.Examples.In.A.Nutshell.3rd.EditioneBook-LiB.chm
Oreilly.Java.Extreme.Programming.Cookbook.eBook-LiB.chm
OReilly.Java.Management Extension.pdf
OReilly.Java.Message Work.pdf
OReilly.Java.Network Prorrajhing, 2ngs Edition.pdf
OReilly.Java.Network.Programming.Third.Edition.Oct.2004.eBook-DDU.chm
OReilly.Java.NIO.pdf
OReilly.Java.performance tuning.pdf
Oreilly.Java.Performance.Tuning.2nd.Edition.eBook-LiB.chm
OReilly.Java.Programming en linux.pdf
OReilly.Java.Programming WWighh wrgie Jdbc.pdf
OReilly.Java.Rmi.pdf
Oreilly.Java.Script.And.DHTML.Cookbook.eBook-LiB.chm
OReilly.Java.Security 2 ª Edition.pdf
OReilly.Java.server Pages.pdf
Oreilly.Java.Server.Pages.3rd.Edition.eBook-LiB.chm
OReilly.Java.Servlet Programming.pdf
Oreilly.Java.Servlet.And.JSP.Cookbook.eBook-LiB.chm
OReilly.Java.Threads.3rd.Edition.Sep.2004.eBook-DDU.chm
OReilly.Java.Web Services.pdf
Oreilly.JavaScript.Pocket.Allusion.2nd.Edition.iNT.eBook-LiB.chm
OReilly.JavaServer.Pages 2 ª Edition.pdf
OReilly.JavaServer.Pages Pockfe Reference.pdf
OReilly.Learning.Perl, Tercera Edition.chm
Oreilly.Learning.Perl.Objects.References.And.Modules.eBook-LiB.chm
OReilly.Learning.PHP.5.Jul.2004.eBook-DDU.chm
OReilly.Learning.PHP.5.Jul.2004.FIXED.eBook-DDU.chm
Oreilly.Learning.Python.2nd.Edition.eBook-LiB.chm
OReilly.Learning.Python.chm
OReilly.Learning.Red.Hat.Enterprise.Linux.and.Fedora.4th.Edition.Apr.2004.eBook-DDU.chm
Oreilly.Learning.RedHat.Linux.3rd.Edition.eBook-LiB.chm
OReilly.Learning.the bash Shell - 2 º Edition.chm
OReilly.Learning.

Similar posts: levitra 2003 latest

Don't get me wrong WebMD has some good patient education materials; however, I think some people can take it to far. I've really never been on WebMD but I'm assuming there is a place where you can put in all your symptoms and it will pull up every scary diagnosis known to man. WebMD is not the place for hyperchondriacs!

Well yesterday and today I got to visit with the ultimate hyperchondriac. So this patient came to me yesterday after having what he thought was a CVA (cerebro vascular accident a.k.a stroke) on Saturday. The story is that he was out shopping in the heat and suddenly felt funny in the head and had some generalized weakness. So after going inside in the air conditioner he felt much better. Immediately he believe he was having a heat stroke. So what does he do but get on WebMD when he gets home. I examine him on Monday and he shows no signs of stroke. He is a 50 year old male that hasn't had a physical in a while so I suggest we get some baseline labs and schedule a time to come in for a complete physical. End of story....NOPE!

This morning he came back in to get his fasting labs; however, after leaving the clinic he starts to feel funny again so he decides to head on over to the ER. Well the triage nurse told him to go back to his primary care physician which is me. So this morning I see him again in clinic. We go over the symptoms again and come to find out he is a nurse and he works for the local mental health/mental retardation organization. Well this doesn't help anything because he has a knowledge of things. He continues to tell me that he thinks he is having either mini strokes, he has an aneurysm, or increased intracranial pressure. I do another exam which is normal. I finally tell him I think he is anxious about his health and that is making him have these "funny feelings." So then I decide I want to put him on an antidepressant well he doesn't want that because they are psycotropic (whatever that means). Then I convince him to try a non-addictive anxiety medicine. Finally he agrees after a lot of convincing and I send him on his way. End of story right...NOPE!

So later in the afternoon he tried to call the clinic to set up a colonoscopy which we do not do in the clinic. I happen to get on the phone with him and he has one more question. He wants to know if I need to check a PT/INR which is what we check on people who are on some sort of blood thinner. I guess he thought his blood was either to thin/thick and needed that checked. I once again reassured him that this was an unnecessary test. So tomorrow when I get his lab results back I'm sure hoping everything comes back normal because I don't know if I can handle anymore WebMD searches by this gentleman.

Similar posts: webmd health